Last edition
News about "Commercialise Keytruda Biosimilar "
Zydus to Commercialise Keytruda Biosimilar FYB206 in US and Canada
Zydus Lifesciences has entered into an exclusive licensing agreement with Germany-based Formycon AG to commercialise FYB206, a biosimilar of the immunotherapy drug Keytruda (pembrolizumab), in the United States and Canada.
Commercialise Keytruda Biosimilar | 10/12/2025 | By Darshana | 163
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members